SEC – ‘UPLOAD’ from 6/2/22 re: Bio-Path Holdings Inc. – ‘TEXT-EXTRACT’

On:  Thursday, 6/2/22, at 2:30pm ET   ·   Delayed-Release:  Filing ¶  –  Release Delayed   ·   Accession #:  0-22-5989

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Comment or Other Letter from the SEC   —   Delayed-Release

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: LETTER      Comment or Other Letter from the SEC                 PDF     37K 
 2: TEXT-EXTRACT  Comment or Other Letter from the SEC - PDF's         1      5K 
                Text                                                             

‘TEXT-EXTRACT’   —   Comment or Other Letter from the SEC – PDF’s Text

United States securities and exchange commission logo                           

June 2, 2022                                  

Peter Nielsen                                                     
President and Chief Executive Officer                             
BIO-PATH HOLDINGS INC                                             
4710 Bellaire Boulevard, Suite 210                                
Bellaire, Texas 77401                                             

                                                     Re: BIO-PATH HOLDINGS
INC                                                                             
                                                    Registration
Statement on Form S-3                                                           
                                                          Filed May 27, 2022
                                                           File No. 333-265282

Dear Mr. Nielsen:                                                 

        This is to advise you that we have not reviewed and will not
review your registration                                                        
statement.                                                        

      Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you                                                     
      that the company and its management are responsible for the accuracy and
adequacy of their                                                               
     disclosures, notwithstanding any review, comments, action or absence of
action by the staff.                                                            

             Please contact Michael Davis at 202-551-4385 or Celeste Murphy at
202-551-3257 with                                                               
any questions.                                                    

Sincerely,                                    

Division of Corporation Finance               

Office of Life Sciences                       
      cc:                                              William R. Rohrlich, II

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘UPLOAD’ Filing		Date		Other Filings
Filed on:		6/2/22		UPLOAD
		5/27/22		S-3,  UPLOAD
				List all Filings